CVS Caremark (CVS) Tops Q1 EPS by 4c; Guides Q2, Narrows FY13 Outlook
Tweet
Share
E-mailGet Alerts CVS Hot Sheet
Join SI Premium – FREE
CVS Caremark (NYSE: CVS) reported Q1 EPS of $0.83, $0.04 better than the analyst estimate of $0.79. Revenue for the quarter came in at $30.76 billion versus the consensus estimate of $30.36 billion.
* Retail pharmacy same store prescription volumes increased 2.0%; 4.7% on a 30-day equivalent basis
* Retail pharmacy same store sales declined 2.3% due to new generic introductions; front store same store sales increased 1.4%
Sees FY2013 EPS of $3.89-$4.00, versus the consensus of $3.97.
Sees Q2 2013 EPS of $0.94-$0.97, versus the consensus of $0.94.
For earnings history and earnings-related data on CVS Caremark (CVS) click here.
* Retail pharmacy same store prescription volumes increased 2.0%; 4.7% on a 30-day equivalent basis
* Retail pharmacy same store sales declined 2.3% due to new generic introductions; front store same store sales increased 1.4%
Sees FY2013 EPS of $3.89-$4.00, versus the consensus of $3.97.
Sees Q2 2013 EPS of $0.94-$0.97, versus the consensus of $0.94.
For earnings history and earnings-related data on CVS Caremark (CVS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Netflix climbs following Ackman stake, up 1.8%
- Fermi Inc. (FRMI) Reports Q2 Loss of $0.04
- Kolibri Global Energy Inc. (KGEI) Misses Q2 EPS by 2c
Create E-mail Alert Related Categories
Earnings, Guidance, Retail SalesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
